Table 1.

Inclusion and exclusion criteria

Inclusion criteria	Exclusion criteria
Optimal heart failure therapy in accordance with European and national guidelines	CRT-D/−P implanted < 90 days
LVEF ≤ 0.40	Uncorrected severe valvular disease
eGFR > 30 mL/min/1.73 m2	Non-compliance
BMI < 45 kg/m2	Use of metalozone
NYHA class I–III	NYHA class IV
Age > 18 years	Age > 85 years
	Dementia
	Admission for HF < 30 days
If T2D – optimal treatment in accordance with European and national guidelines	Admission for hypoglycemia < 12 months
If T2D – stable doses of anti-glycemic treatment for 30 days	Known sustained VT
If T2D – HbA1c 6.5–10.0%	Symptomatic hypotension and systolic BP < 95 mmHg
	Unable to perform an exercise test
	Immobilization
	Pregnancy
	Participation in other medical trials
	Previous intolerance of Empagliflozin or excipients

LVEF left ventricular ejection fraction, eGFR estimated glomerular filtration rate, BMI body mass index, NYHA New York Heart Association, T2D type 2 diabetes, HbA1c hemoglobin A1c, CRT-D/−P cardiac resynchronization therapy with defibrillator (−D) or without defibrillator (−P), HF heart failure, VT ventricular tachycardia, BP blood pressure